Re-examining Permissive Hypercapnia in ARDS: A Narrative Review.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 29175086.
- Also identified by DOI 10.1016/j.chest.2017.11.010.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Lung-protective ventilation (LPV) has become the cornerstone of management in patients with ARDS. A subset of patients is unable to tolerate LPV without significant CO<sub>2</sub> elevation. In these patients, permissive hypercapnia is used. Although thought to be benign, it is becoming increasingly evident that elevated CO<sub>2</sub> levels have significant physiological effects. In this narrative review, we highlight clinically relevant end-organ effects in both animal models and clinical studies. We also explore the association between elevated CO<sub>2</sub>, acute cor pulmonale, and ICU mortality. We conclude with a brief review of alternative therapies for CO<sub>2</sub> management currently under investigation in patients with moderate to severe ARDS.
Medical subject headings
- Clinical Protocols
- Hypercapnia
- Respiration, Artificial
- Respiratory Distress Syndrome